Given the outcome gains seen with brensocatib in WILLOW, which positive signals—such as fewer exacerbations, better quality of life, less antibiotic use, and preserved FEV1—were likewise confirmed in the ASPEN trial?

Professor Michael Loebinger, MA, FRCP, PhD

Director of the Lung DivisionaClinical Director of Laboratory MedicineaDeputy Medical DirectorConsultant Respiratory MedicineRoyal Brompton & Harefield HospitalsProfessor of Practice (Respiratory Medicine)National Heart and Lung InstituteImperial ...